Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks o...
Vir Biotechnology, Inc. (VIR)
Company Research
Source: Yahoo! Finance
– Conference call scheduled for June 5, 2024, at 6:00 a.m. ET / 12:00 p.m. CEST – SAN FRANCISCO, June 05, 2024 BUSINESS WIRE )--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, for the treatment of people living with chronic hepatitis delta. Preliminary data from the Phase 2 trial show treatment with tobevibart alone or in combination with elebsiran was generally well tolerated and participants achieved high rates of virologic response at weeks 12 and 24, durable virologic response through 48 weeks, and high rates of ALT normalization. The Company will host an investor conference call on June 5 at 6:00 a.m. ET / 12:00 p.m. CEST to discuss these data. Originally accepted as a late-breaker poster , these data will be presented in more detail in an oral presentation on J
Show less
Read more
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology (VIR) Up on Positive Data From HDV Study [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at Morgan Stanley from $12.00 to $15.00. They now have an "equal weight" rating on the stock.MarketBeat
- Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at Needham & Company LLC from $15.00 to $19.00. They now have a "buy" rating on the stock.MarketBeat
- Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.MarketBeat
VIR
Earnings
- 5/2/24 - Beat
VIR
Sec Filings
- 6/12/24 - Form 4
- 6/12/24 - Form 4
- 6/11/24 - Form 144
- VIR's page on the SEC website